Philip Vorhies is a seasoned biopharmaceutical executive with a rich background spanning more than two decades in the field of life sciences. He has traversed the landscape from nurturing seed stage start-ups to contributing his expertise to major Fortune 50 corporations, consistently delivering a strong track record of value generation.

Throughout his career, Philip has played pivotal roles in orchestrating the successful launch of over 20 different products and devices, including multiple rare diseases. His leadership has spanned cross-functional teams, encompassing areas such as commercialization, market access, medical affairs, regulatory compliance, and clinical development. His therapeutic area experience is particularly robust in central nervous system (CNS), immunology, inflammation, oncology, dermatology, and several others. Furthermore, Philip boasts impressive experience in the C-suite, focusing on Cell & Gene therapy, working on the development and commercialization of transformative assets like VST, CAR-T, and TIL.